Bristol Myers Squibb (BMS) has reported Q1 2026 revenue of approximately USD 11.5 billion, a 3% increase. The company categorises its products into growth and legacy portfolios, with the growth portfolio contributing USD 6.2 billion, a 12% increase. Key growth drivers included the cardiovascular drugs Eliquis (apixaban), up 16% to USD 4.1 billion, and Camzyos (mavacamten), which more than doubled to USD 314 million. Sales of the intravenous formulation of Opdivo (nivolumab) declined 5% to USD 2.3 billion, while its subcutaneous version, Opdivo Qvantig, generated USD 163 million.
BMS provided an update on its key pipeline milestones, announcing that data from the registrational trial for its autoimmune CAR-T therapy, zolacaptagene autoleucel, is now expected in 2027, a year earlier than previously anticipated. The company also removed two pipeline projects, including a CD40/FAP bispecific antibody (BsAb). BMS maintained its full-year 2026 revenue guidance of USD 46 billion to USD 47.5 billion.

According to PharmCube's NextBiopharm® database, zolacaptagene autoleucel is under development for 10 indications globally. Click here to request a free trial for NextBiopharm®.